Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00380939 · ClinicalTrials.gov registry record · Phase 4

This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.

A Phase 4 study of Coronary Arteriosclerosis, sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
600
Enrollment target
20
Study locations

NCT00380939: Completed Phase 4 study of Coronary Arteriosclerosis, sponsored by Pfizer.

NCT00380939 is a Phase 4 study of Coronary Arteriosclerosis that has completed, run by Pfizer. The registered enrollment target is 600 participants, below the 663-participant average among 11 other Coronary Arteriosclerosis trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00380939, a Phase 4 study of Coronary Arteriosclerosis, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
600 participants
Enrollment target
20
Study locations

Study Summary

This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy. A substudy will examine the effect of these treatments on brachial artery vasoactivity.

Conditions Studied

Interventions

  • DRUG Atorvastatin
  • DRUG Pravastatin

Study Locations (20)

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - San Diego

Michigan

  • Pfizer Investigational Site - Kalamazoo
  • Pfizer Investigational Site - Royal Oak
  • Pfizer Investigational Site - Saint Clair

New York

  • Pfizer Investigational Site - Albany
  • Pfizer Investigational Site - New York
  • Pfizer Investigational Site - Williamsville

Florida

  • Pfizer Investigational Site - BLUE Island
  • Pfizer Investigational Site - Gainesville

Arkansas

  • Pfizer Investigational Site - Little Rock

Colorado

  • Pfizer Investigational Site - Denver

Georgia

  • Pfizer Investigational Site - Atlanta

Illinois

  • Pfizer Investigational Site - Chicago

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 1999-04
Est. Completion 2000-12
Phase Phase 4
Pfizer

1,845 total trials

What the finished NCT00380939 record still lists

NCT00380939 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 663-participant average among 11 other Coronary Arteriosclerosis trials with a reported enrollment target (10% lower).

The record links to 1 condition, with Coronary Arteriosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Atorvastatin is the first listed.

NCT00380939 names 20 study sites across 13 states, led by California, Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT00380939 about?

NCT00380939 is a clinical study titled "This Study Uses Ultrasound to Determine Whether Atorvastatin or Pravastatin Effects the Progression of Coronary Plaque.". This study was designed to assess the effects on coronary artery plaque using aggressive lipid-lowering therapy versus moderate lipid-lowering therapy. A substudy will examine the effect of these treatments on brachial artery vasoactivity.

What is the current status of trial NCT00380939?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 1999-04. Estimated completion is 2000-12.

What conditions does trial NCT00380939 study?

This clinical trial studies the following conditions: Coronary Arteriosclerosis.

What interventions are being tested in trial NCT00380939?

The interventions under investigation include: Atorvastatin (DRUG), Pravastatin (DRUG).

Who is sponsoring clinical trial NCT00380939?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00380939 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Arteriosclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00380939's enrollment target sits among peer trials

600 4th of 11 higher than 8 of 11 other Coronary Arteriosclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Arteriosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00380939, the US trial registry maintained by the National Library of Medicine. NCT00380939 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.